Specifically, when ADAMTS13 −/− were treated with prophylactic rhADAMTS13 prior to vWF administration, no mice showed clinical, hematologic, or pathologic signs of TTP. This evidence concerns the gene ADAMTS13 and thrombotic thrombocytopenic purpura.